# A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

> **NCT05072080** · PHASE3 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 3258 (actual)

## Conditions studied

- Chikungunya Virus

## Interventions

- **BIOLOGICAL:** CHIKV VLP/adjuvant
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05072080
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-29
- **Primary completion:** 2023-04-03
- **Final completion:** 2023-04-03
- **Target enrollment:** 3258 (ACTUAL)
- **Last updated:** 2024-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05072080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05072080, "A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05072080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*